Managing Director of the AI Center of Excellence in Deloitte Advisory, reporting to the Chief Strategy Officer. In 36 months, built a $360M AI business by building a team of 80 AI Researchers & Engineers and leveraging the business infrastructure of Deloitte Advisory. Starting with no existing Deep Learning model development capability to shipping 100+ production models in solutions for Cyber Security, Healthcare Fraud/Waste/Abuse detection, Financial and Accounting Controls and Enterprise Risk Management. Metrics exceeded plan significantly across all dimensions including sales, revenue, and margin improvements. Current AI modeling efforts include enabling Deloitte products in Cyber Security, Predictive Maintenance, Enterprise Risk Management, M&A activities, and ERP implementations while expanding efforts in fraud/waste/abuse (healthcare and financial services) and Financial Systems and Controls.Established scalable code-as-platform AI/ML model development platform that enables an elastic resource group to build multiple models across multiple programs simultaneously. Primarily deployed at hyper-scaler “clould” providers, elastic infrastructure allows us to scale as we have more teams working in parallel, while providing a consistent set of tools to the AI/ML Engineers (Data Scientists).Established three academic research partnerships with leading universities. Sponsored PhD students in the execution of a shared university/industry research roadmap that focused student research on areas of commercial opportunity. Co-published numerous papers and developed novel techniques in some of the most challenging areas of AI, Graph, and Cyber.Routinely consult with C-Suite leaders in mid-to-large organizations in helping establish AI programs including: operating models, talent strategies, platform strategy (Data and Compute), and governance/trust/risk programs.

Research Contributor: Program in Placebo Studies. For the past ten years, an informal network of researchers at Harvard Medical School has taken a leading role in the field of placebo studies. In July 2011, Beth Israel Deaconess Medical Center invited these researchers to create the Harvard-wide Program in Placebo Studies and the Therapeutic Encounter (PiPS). Contribute research findings, advise students on research approaches, and provide guest lectures.http://programinplacebostudies.org

Lead a team of data scientists and machine learning engineers in leveraging large-scale, distributed systems in building, testing and validating predictive/statistical and machine learning models, leveraging Python, R, Spark, TensorFlow, Keros, PyTorch, Spotfire, and other analytical tools. Lead an organization in developing and applying novel advances in Neural Network approaches to medicines development, in areas such as:• Molecular Design of compounds, antibodies, and enzymes• Target Identification and Validation• Imaging Applications across Functional Genomics, Histology, Bioreactors• Patient Stratification• Portfolio optimization and Clinical OperationsLed AI/ML strategy development effort for GSK R&D Technology Strategy. Accountable for implementing strategy and delivering projects supporting GSK R&D transformational goals.Representative problems include: analysis of gene expression and biological pathway data leveraging machine learning techniques to isolate disease-associated genes in diseased tissue; big data, big compute Genome-Wide Association Studies using 500k patients from the UK Biobank and 50k Whole Exomes along with associated phenotype data; consolidation of GSK legacy clinical data to analyze laboratory data to support drug repositioning opportunities.

TransCelerate BioPharma Inc. is a non-profit organization focused on advancing innovation in research and development (R&D), identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients.The Placebo and Standard of Care (SOC) Data Sharing Initiative creates a framework for data sharing that offers the potential to reduce the patient population needed to be enrolled in a clinical trial, as it is intended to allow for the leveraging of data from previous studies (historical controls). It would thereby decrease the time spent on cumulative trial execution, and assist in the acceleration of new therapies to patients. It also offers the potential for more rapid understanding of safety signals to better manage patient safety during clinical trials, as well as identify approaches to deliver more accurate study design and statistical power calculations.

Responsible for strategy and execution of information technology efforts in translational research and bioinformatics for Pfizer’s Research Units. Manage solutions and services supporting target validation, biomarker identification, disease understanding, and patient stratification including information systems and services for genetics, transcriptomics, proteomics, clinical phenotypes, and pathway analysis.

Led an interdisciplinary team of scientific and technology experts in applying scientific data to answer drug discovery research questions. Focused on seeking out novel approaches to leveraging legacy clinical trial data, electronic medical record data, and publicly available data to support new hypotheses. Representative projects include the development of an eControls dataset of anonymized placebo and medically stable patients from historical trials for use to provide context to clinicians in ongoing trials, the use of genome-wide association study (GWAS) data and existing data collected on research candidates to identify and validate secondary indications and new potential targets, and analysis of clinical laboratory observations for the purposes of drug repositioning across a number of therapeutic areas.

Led a team of 80+ colleagues and contractors in the delivery of Information Architecture and R&D Global Data Warehousing services and solutions. Responsible for executing design and modeling on key strategic projects across the RDMi portfolio and providing design reviews, oversight, coaching, and best practices on the remainder of the portfolio. Built a team of architects to develop high level information flows/plans for the other project teams to execute against. Provided direction and design approval for data integration projects across Research, Development, and Medical business domains. Key impacts were in the delivery of a portfolio of integration and visualization projects, direct design contribution to key transactional projects (CTRM, eProtocol, Biobook), in the development of strategy (Global Data Warehousing Strategy, data strategy of the domain business roadmaps), and in the capture and presentation of meta-data (Data Catalog).

Managed a portfolio of projects delivering information and decision support applications to Pfizer’s Worldwide Development leadership and drug development project teams. Led two separate governance (BIG) teams (CTSI and RMDS), partnering with a broad group of business stakeholders to develop a cohesive strategy and execute on a portfolio of IT projects directly supporting business priorities. Led multiple project teams consisting of over 80 contract personnel, including project managers, business analysts, technical analysts, developers, and support personnel in providing application development and support to six Worldwide Development sites in the US, Europe, and Japan. Provided leadership for three major programs of work in support of achieving Informatics and WWD goals. Worked closely with key business stakeholders and Informatics partners across multiple international sites and Pfizer divisions to define and implement overall systems strategy, including defining next generation solutions that seek to maximize and leverage the scale of Pfizer. Developed a broad network of partners across the Worldwide Technology organization, including Data Warehousing and Business Intelligence, Information Architecture, Research Informatics, the Finance IT organization, and shared services. Demonstrated the ability to deliver to specific business customers within the context of broader organizational objectives.

Managed and led a core team of 12 developers, analysts, and support personnel providing application development and support to four Pfizer PGRD sites in the US and Europe. Supported a user base of over 1,000 personnel in the management and monitoring of clinical trials. Project consisted of a number of ongoing sub-projects relating to clinical trial tracking and performance metrics, primarily leveraging data warehousing technologies to compile and analyze large volumes of transactional data and report metrics and analytics via the web. Worked closely with key business (DevOps) stakeholders to define and implement overall systems strategy, define and compile functional requirements, develop project plans, manage system development, and deliver releases while managing ongoing support and training development.

Responsible for delivering services to clients, new business development, engagement economics, performance management, and a national role as the operations manager for the Business Metrics service line of the Global Capital Markets practice. Managed multiple risk consulting information technology projects including a large engagement to deliver an analytical web application that provided comprehensive risk intelligence and performance metrics surrounding the organization’s multi-billion dollar portfolio. Managed and executed multiple projects performing quantitative analysis, statistical analysis, data analysis and enterprise risk consulting services for an array of clients including the following representative clients: Bayer Pharmaceuticals, Massachusetts Mutual Life Insurance Company, New England Financial Services/ MetLife, SunLife of Canada, MFS, Citizens Bank, Government National Mortgage Association (Ginnie Mae), Nextel, Priceline.com, DirectHit.com, and AdDirect.com.

U.S. Coast Guard Research and Development Center, Groton, CT Staff Engineer: As a staff engineer, developed software and prototype systems, field-tested prototype designs, established equipment interfaces with operational USCG systems, and assessed wireless digital communications. U.S. Coast Guard Cutter ACACIA (WLB 406), Charlevoix, MIOperations Officer:Third in command of ship with a crew of 55 people. As Operations Department head, responsible for direct line management of 20 personnel, including: performance evaluations, resource management, mentoring. Responsibilities included planning for, and leading personnel in, the execution of operational missions to include Buoy and Lighthouse Servicing, Search and Rescue, Port Security in Haiti during Operation Uphold Democracy, Icebreaking on Great Lakes, and Caribbean Law Enforcement Patrols. Managed functions relating to navigation, communications, administration, medical, and supply. Awarded the Armed Forces Expeditionary Medal; Awarded the Humanitarian Service Medal three times for service in the Caribbean.